People News

Share this content:
Oscient Pharmaceuticals Corporation has appointed two senior leaders with extensive cardiovascular experience from the highly successful commercial team at Kos Pharmaceuticals to key sales and marketing leadership positions. Aaron Berg has been named VP of marketing and Mark Glickman, VP of sales, effective today. Berg and Glickman will report directly to Nick Colangelo, EVP. Berg served as VP of marketing at Kos where he directed all marketing activities for in-line and new products, including strategic and tactical business planning and execution, market research and lifecycle management and held concurrent responsibility as VP, sales for the Eastern division leading up to Abbott's acquisition of Kos. Prior to his promotion to VP of marketing,  Berg was executive director of marketing at Kos, where he directed brand strategy for the Kos flagship product, Niaspan. Berg joined Kos from GlaxoSmithKline where he was the senior product manager for Avandia. Previously, Berg held positions of increasing responsibility in sales, disease management and marketing at Schering-Plough and helped make IMDUR the highest prescribed long-acting nitrate product worldwide with sales in excess of $200 million. Following the Abbott acquisition of Kos Pharmaceuticals, Glickman joined Bayer Healthcare's Diabetes Care Division as VP of sales. While at Kos, Glickman helped build the commercial organization by holding various positions including director of marketing and regional sales director before his promotion to VP of sales. As director of marketing, Glickman was responsible for the launch of Advicor, the second commercial product for Kos. Prior to Kos, he was at Bristol-Myers Squibb as a cardiovascular product manager and senior product manager for Plavix and Vanlev, where, during his tenure, he contributed to a $400 million increase in Plavix revenue. Glickman also was employed by Baxter Healthcare as a sales specialist, regional sales manager and then as general manager of sales, for a $100 million medical and surgical supply portfolio.

Prestwick Pharmaceuticals, a privately held biotechnology company, announced that it has added Robert Radie to its senior management team as EVP and chief business officer. Radie joins Prestwick most recently from Morphotek, where he was VP of project management and chief business officer, and helped lead the successful acquisition of Morphotek by Eisai earlier this year. Radie will be responsible for Prestwick's commercial operations and business development activities that support its portfolio of drugs in development. Prestwick's portfolio of drugs in development includes its lead product candidate, tetrabenazine, a highly selective and reversible dopamine depletor in Phase 3 clinical trials for potential use as a treatment for chorea associated with Huntington's Disease. Prior to Morphotek, Radie worked with Horner as SVP of Strategic Projects and Planning at Vicuron Pharmaceuticals, where he was responsible for marketing and sales, corporate strategy and business development. In 2005, he played a key role in the acquisition of Vicuron by Pfizer for $1.9 billion. Before joining Vicuron, Radie spent his professional career in positions of increasing responsibility at Eli Lilly. During his tenure at Eli Lilly he managed several successful product launches and led national sales forces, most recently as the director of sales for Eli Lilly's critical care division. Radie oversaw the U.S. deployment for the critical care division, which included a team of 231 sales representatives and 23 district managers. Radie also contributed to the shaping of Eli Lilly's reimbursement strategy which was designed to ensure that hospital products gained timely formulary approval. Prior to that, as director of sales for Eli Lilly's diabetes top performing business unit in the northeast region, Radie launched three new products, including Actos and Humalog Mix 75/25, and led a significant expansion of that sales force. He also played an important role in the launch of Prozac and Zyprexa, Eli Lilly's two leading neuroscience drugs.

Mary Ann Kim recently joined MediZine, a leader in consumer health educational marketing, as senior marketing Mmanager, brand services. In her new role, Kim is responsible for the marketing and branding for MediZine's cross platform programs including MediZine's Healthy Living, REMEDY, Diabetes Focus, Diabetes Focus Espanol, MDminute, and REMEDYDirect.  Prior to joining MediZine, Kim served as director, partnership marketing at AWE, an entertainment marketing agency under Omnicom, where she was responsible for aligning strategic partnerships between clients and consumer brands, as well as business development. Kim has also held positions at Billboard as promotion manager and Fine Living magazine.
Share this content:
Scroll down to see the next article